
´
PLUVICTO is the first and only PSMA-targeted radioligand therapy NOW APPROVED after only 1 ARPI1
Choose PLUVICTO: Proven in 2 large phase 3 trials and ~20K patients with PSMA+ mCRPC treated from launch to date.1-4,†
ARPI, androgen receptor pathway inhibitor; mCRPC, metastatic castration-resistant prostate cancer; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.
*For patients considered appropriate to delay taxane-based chemotherapy.1
†Based on data from February 2025.